|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||37.36 - 37.56|
|52 Week Range||29.45 - 37.79|
|Beta (3Y Monthly)||0.43|
|PE Ratio (TTM)||24.46|
|Forward Dividend & Yield||1.07 (2.87%)|
|1y Target Est||N/A|
Dirk Van de Put, CEO of Mondelēz International (NASDAQ: MDLZ), talks to Yahoo Finance's Julia La Roche about the company's global strategy and reveals the findings of a recent study about snacking behavior.
Amazon third-party sellers are suspended from making sales due to an email glitch. Yahoo Finance’s Dan Roberts, Heidi Chung and Julia La Roche discuss on YFi-AM.
Zillow’s shares soar after the online real estate company beat revenue estimates for the third-quarter. Yahoo Finance’s Dan Roberts, Julia La Roche and Heidi Chung discuss on YFi AM.
Yahoo Finance's Dan Roberts, Julia La Roche, and Heidi Chung discuss the long-awaited streaming platform, Disney+, and how it will disrupt the streaming wars.
Teva shares are climbing after the pharmaceutical company raised its guidance for the year. Yahoo Finance’s Akiko Fujita and Ines Ferre break down the quarterly earnings results on The Ticker.
Tinder Co-founder Sean Rad joins Yahoo Finance's Zack Guzman, Kristin Myers and Julia La Roche to discuss the latest developments on the $2B lawsuit against IAC. Rad also discusses the outlook on the dating app industry and chats about his new nonprofit.
A group of former Tinder executives sued IAC for $2 billion after ex-employees accused IAC for undervaluing the dating app and allegedly being cheated out of stock options. Tinder's Co-Founder Sean Rad joins Yahoo Finance's Zack Guzman and Julia La Roche to discuss the latest developments on the lawsuit, on YFi PM.
Microsoft Japan tested out a 4-day workweek for all of August as part of its Work-Life Choice challenge. Employees were still paid for their Fridays off, and the results showed that employee productivity rose by 40%, the number of papers printed was reduced by 58%, and electricity consumption was reduced by 23%. Japan has some of the longest working hours in the world, with 1 in 4 companies expecting their employees to work 80 hours overtime a month, according to a government study.
Goldman Sachs is making changes to be more family-friendly for its employees. In an internal memo obtained exclusively by Yahoo Finance, Goldman says it will offer all new parents 20 weeks paid leave, regardless of caregiver status. The bank will also add other benefits to help all groups on their path to parenthood.
Berkshire Hathaway has reported a record high cash pile to end the third quarter. Yahoo Finance’s Dan Roberts, Brian Cheung and Julia La Roche discuss on YFi-Am.
The National Highway Traffic Safety Administration is looking into potential defects in Tesla's battery packs after "an alarming number of car fires that have occurred worldwide," according to a letter the regulator sent to the electric carmaker. Yahoo Finance’s Dan Roberts, Brian Cheung and Julia La Roche discuss on YFi AM.
AbbVie (ABBV) submits a regulatory application with the FDA seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan.
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study. Roche, which plans to seek approval for the investigational medicine this year, said its SUNFISH trial demonstrated statistically significant improvements in patients aged 2-25 years with Type 2 or 3 SMA, compared to a placebo. Biogen's Spinraza, approved in 2016, lists at $750,000 in year one and $375,000 thereafter, while Novartis's Zolgensma is the costliest one-time treatment at $2.1 million.
Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ...